We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
Cap. Flow
-$105M
Cap. Flow %
-10.94%
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$20.8M
2
SGMT icon
Sagimet Biosciences
SGMT
+$19.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$19.1M
4
CELC icon
Celcuity
CELC
+$16.5M
5
ORKA
Oruka Therapeutics
ORKA
+$13.5M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$57.9M
2
NUVL
Nuvalent
NUVL
+$36.4M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$23.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$18.5M
5
KOD icon
Kodiak Sciences
KOD
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Miscellaneous 6.61%
3 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLXC
26
Helix Acquisition Corp III
HLXC
$238M
$12.5M 1.3%
1,177,821
-31,165
-3% -$320K
ALXO icon
27
ALX Oncology
ALXO
$277M
$11.9M 1.24%
+5,744,757
New +$10.3M
MANE
28
Veradermics Inc
MANE
$4.09B
$11.7M 1.21%
+95,000
New +$8.9M
XENE icon
29
Xenon Pharmaceuticals
XENE
$5.81B
$11.3M 1.17%
186,821
-10,938
-6% -$607K
AVLN
30
Avalyn Pharma
AVLN
$1.54B
$10.9M 1.13%
+330,487
New +$9.54M
BIIB icon
31
Biogen
BIIB
$32.3B
$10.4M 1.08%
48,101
-2,866
-6% -$548K
ACRS icon
32
Aclaris Therapeutics
ACRS
$885M
$10.3M 1.07%
+1,946,482
New +$8.68M
CERS icon
33
Cerus
CERS
$534M
$10.1M 1.05%
3,472,737
+296,190
+9% +$718K
AVTX icon
34
Avalo Therapeutics
AVTX
$1.05B
$9.25M 0.96%
+500,402
New +$7.91M
BNTC icon
35
Benitec Biopharma
BNTC
$428M
$9.1M 0.95%
679,826
-37,899
-5% -$450K
PCVX icon
36
Vaxcyte
PCVX
$8.9B
$8.43M 0.88%
145,000
+19
+0% +$1.03K
WGS icon
37
GeneDx Holdings
WGS
$2.57B
$8.39M 0.87%
+122,269
New +$6.95M
SVRA icon
38
Savara
SVRA
$1.08B
$8.35M 0.87%
1,355,459
-75,523
-5% -$405K
OVID icon
39
Ovid Therapeutics
OVID
$547M
$8.34M 0.87%
3,101,129
+2,101,129
+210% +$5.42M
ORIC icon
40
Oric Pharmaceuticals
ORIC
$1.37B
$8M 0.83%
738,873
-361,137
-33% -$3.27M
ORIC icon
41
CALL
Oric Pharmaceuticals
ORIC
$1.37B
$7.39M 0.77%
+682,600
New +$6.19M
GLUE icon
42
CALL
Monte Rosa Therapeutics
GLUE
$1.14B
$7.26M 0.75%
+300,000
New +$5.67M
CMPS
43
Compass Pathways
CMPS
$1.9B
$7.12M 0.74%
503,382
+203,382
+68% +$2.06M
CGEN icon
44
Compugen
CGEN
$246M
$6.81M 0.71%
3,184,257
-131,588
-4% -$330K
SLDB icon
45
Solid Biosciences
SLDB
$1.05B
$6.68M 0.69%
+668,450
New +$5.07M
ABVX
46
CALL
Abivax
ABVX
$9.89B
$6.66M 0.69%
+50,000
New +$5.66M
IBIO icon
47
iBio
IBIO
$67.6M
$6.16M 0.64%
3,520,490
+3,294,490
+1,458% +$5.89M
IRON icon
48
Disc Medicine
IRON
$3.07B
$6.06M 0.63%
82,800
-113,228
-58% -$7.78M
ALKS icon
49
Alkermes
ALKS
$7.95B
$5.95M 0.62%
113,494
-346,820
-75% -$13.5M
SYRE icon
50
Spyre Therapeutics
SYRE
$7.97B
$5.32M 0.55%
59,959
-126,659
-68% -$9.24M
1
2
3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.

  • Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
  • Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
  • Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
  • Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
  • Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
  • Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
  • Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.